Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study

Archie Digital Collections

Show simple item record

dc.contributor.author Kim, Hyo Song
dc.contributor.author Kim, Eun Kyoung
dc.contributor.author Jun, Hyun Jung
dc.contributor.author Oh, Sung Yong
dc.contributor.author Park, Keon Woo
dc.contributor.author Lim, Do Hyeong
dc.contributor.author Lee, Soon Il
dc.contributor.author Kim, Jung-Han
dc.contributor.author Kim, Kyoung Mee
dc.contributor.author Lee, Dae Ho
dc.contributor.author Lee, Jeeyun
dc.date.accessioned 2010-06-08T19:41:32Z
dc.date.available 2010-06-08T19:41:32Z
dc.date.issued 2010-04-28
dc.identifier http://dx.doi.org/10.1186/1471-2407-10-167
dc.identifier.uri http://hdl.handle.net/2271/838
dc.description.abstract Abstract Background We performed multicenter study to define clinical characteristics of noncutaneous melanomas and to establish prognostic factors patients who received curative resection. Methods Of the 141 patients who were diagnosed of non-cutaneous melanoma at 4 institutions in Korea between June 1992 and May 2005, 129 (91.5%) satisfied the selection criteria. Results Of the 129 noncutaneous melanoma patients, 14 patients had ocular melanoma and 115 patients had mucosal melanoma. For mucosal melanoma, anorectum was the most common anatomic site (n = 39, 30.2%) which was followed by nasal cavity (n = 30, 23.3%), genitourinary (n = 21, 16.3%), oral cavity (n = 14, 10.9%), upper gastrointestinal tract (n = 6, 4.7%) and maxillary sinus (n = 5, 3.9%) in the order of frequency. With the median 64.5 (range 4.3-213.0) months follow-up, the median overall survival were 24.4 months (95% CI 13.2-35.5) for all patients, and 34.6 (95% CI 24.5-44.7) months for curatively resected mucosal melanoma patients. Adverse prognostic factors of survival for 87 curatively resected mucosal melanoma patients were complete resection (R1 resection margin), and age > 50 years. For 14 ocular melanoma, Survival outcome was much better than mucosal melanoma with 73.3% of 2 year OS and 51.2 months of median OS (P = .04). Conclusion Prognosis differed according to primary sites of noncutaneous melanoma. Based on our study, noncutaneous melanoma patients should be treated differently to improve survival outcome.
dc.title Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study
dc.type Journal Article
dc.date.updated 2010-06-03T00:27:37Z
dc.description.version Peer Reviewed
dc.language.rfc3066 en
dc.rights.holder Kim et al.; licensee BioMed Central Ltd.

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Archie


Advanced Search

Browse

My Account

Sword Copy

Statistics